CARE Ratings (CARERATING) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
14 May, 2026Executive summary
Achieved broad-based growth in FY26, with consolidated revenue from operations rising 18% YoY to ₹473.07 Cr and PAT reaching an all-time high of ₹173.69 Cr, up 24% YoY, with a PAT margin of 33%.
Ratings segment contributed 89% of consolidated revenue, growing 17% YoY to ₹423.05 Cr, while the non-ratings segment grew 19% YoY to over ₹50 Cr.
Board recommended a final dividend of ₹14 per share, bringing the total FY26 dividend to ₹22 per share, subject to shareholder approval.
Significant investments in AI and technology, with 60% of staff using enterprise AI tools and multiple AI-powered platforms launched.
Audited standalone and consolidated financial results for FY26 were approved with unmodified opinions; 55,000 stock options were granted to employees.
Financial highlights
Standalone revenue from operations for FY26 was ₹387.72 Cr, up 15% YoY, with standalone operating profit at ₹187.39 Cr and a margin of 48%.
Consolidated operating profit (EBITDA) for FY26 was ₹197.39 Cr, up 27% YoY, with a margin of 42%.
Standalone PAT for FY26 was ₹174.39 Cr, up 18% YoY, with a margin of 39%.
EPS for FY26 stood at ₹57.06 (consolidated) and ₹58.13 (standalone).
Total consolidated assets as of March 31, 2026, stood at ₹1,10,473.70 lakhs.
Outlook and guidance
FY27 GDP growth projected to moderate to 6.7% due to global oil prices and potential El Niño impact; macro outlook is mixed with global headwinds.
Union Budget 2026-27 expected to support sustained growth with fiscal discipline.
Demand for independent credit risk opinions expected to grow amid uncertainty.
Focus remains on scaling both ratings and non-ratings businesses, with confidence in accelerating non-ratings growth after achieving profitability.
Management will monitor the impact of new labour codes and adjust compensation structures as needed.
Latest events from CARE Ratings
- Strong revenue and margin growth, led by ratings, with regulatory and product developments.CARERATING
Q3 25/2611 Feb 2026 - Revenue and PAT rose 19% and 16% year-over-year, led by ratings business; Board reconstituted committees.CARERATING
Q1 24/2518 Nov 2025 - Strong revenue and profit growth, global expansion, and interim dividend declared.CARERATING
Q2 24/2518 Nov 2025 - Record revenue, profit growth, and international expansion marked a strong FY25.CARERATING
Q4 24/2518 Nov 2025 - Strong profit growth, interim dividend, and strategic subsidiary stake sale in Q2 FY26.CARERATING
Q2 25/2614 Nov 2025 - Double-digit growth in income and profits, with stable governance and clean audit review.CARERATING
Q1 25/268 Aug 2025 - Q3FY25 revenue and profit surged YoY, led by ratings and non-ratings growth.CARERATING
Q3 24/255 Jun 2025